Albumin-based drug designs for pharmacokinetic modulation

References

• Peters T Jr. All about albumin: biochemistry, genetics, and medical applications. San Diego (CA): Academic press; 1996.
   Google Scholar
• YS D, DG M. Characterizing a drug’s primary binding site on albumin. J Pharm Sci. 2003 Feb;92(2):333–343.
   Google Scholar
• Vorum H, Honore B. Influence of fatty acids on the binding of warfarin and phenprocoumon to human serum albumin with relation to anticoagulant therapy. J Pharm Pharmacol. 1996 Aug;48(8):870–875.
   Google Scholar
• Mao H, Hajduk PJ, Craig R, et al. Rational design of diflunisal analogues with reduced affinity for human serum albumin. J Am Chem Soc. 2001;123(43):10429–10435.
   Google Scholar
• Piroli RJ, Passananti GT, Shively CA, et al. Antipyrine and warfarin disposition in a patient with idiopathic hypoalbuminemia. Clin Pharmacol Ther. 1981 Dec;30(6):810–816.
   Google Scholar
• Greenblatt DJ, Koch-Weser J. Clinical toxicity of chlordiazepoxide and diazepam in relation to serum albumin concentration: a report from the Boston collaborative drug surveillance program. Eur J Clin Pharmacol. 1974 Jul 26;7(4):259–262.
   Google Scholar
• Sudlow G, Birkett DJ, Wade DN. The characterization of two specific drug binding sites on human serum albumin. Mol Pharmacol. 1975 Nov;11(6):824–832.
   Google Scholar
• Sudlow G, Birkett DJ, Wade DN. Further characterization of specific drug binding sites on human serum albumin. Mol Pharmacol. 1976 Nov;12(6):1052–1061.
   Google Scholar
• He XM, Carter DC. Atomic structure and chemistry of human serum albumin. Nature. 1992 Jul 16;358(6383):209–215.
   Google Scholar
• Curry S, Mandelkow H, Brick P, et al. Crystal structure of human serum albumin complexed with fatty acid reveals an asymmetric distribution of binding sites. Nat Struct Biol. 1998 Sep;5(9):827–835.
   Google Scholar
• Ghuman J, Zunszain PA, Petitpas I, et al. Structural basis of the drug-binding specificity of human serum albumin. J Mol Biol. 2005 Oct 14;353(1):38–52.
   Google Scholar
• Simard JR, Zunszain PA, Hamilton JA, et al. Location of high and low affinity fatty acid binding sites on human serum albumin revealed by NMR drug-competition analysis. J Mol Biol. 2006 Aug 11;361(2):336–351.
   Google Scholar
• Petitpas I, Bhattacharya AA, Twine S, et al. Crystal structure analysis of warfarin binding to human serum albumin: anatomy of drug site I. J Biol Chem. 2001 Jun 22;276(25):22804–22809.
   Google Scholar
• Al-Harthi S, Lachowicz JI, Nowakowski ME, et al. Towards the functional high-resolution coordination chemistry of blood plasma human serum albumin. J Inorg Biochem. 2019 Sep;198:110716.
   Google Scholar
• Levitt DG, Levitt MD. Human serum albumin homeostasis: a new look at the roles of synthesis, catabolism, renal and gastrointestinal excretion, and the clinical value of serum albumin measurements. Int J Gen Med. 2016;9:229–255.
   Google Scholar
• Plouin PF, Degoulet P, Menard D, et al. IgG versus albumin for measurement of plasma volume in normal and hypertensive men. Eur J Nucl Med. 1978 Jul 1;3(3):183–186.
   Google Scholar
• Rothschild MA, Bauman A, Yalow RS, et al. Tissue distribution of I131 labeled human serum albumin following intravenous administration. J Clin Invest. 1955 Sep;34(9):1354–1358.
   Google Scholar
• Fleck A, Raines G, Hawker F, et al. Increased vascular permeability: a major cause of hypoalbuminaemia in disease and injury. Lancet. 1985 Apr 6;1(8432):781–784.
   Google Scholar
• Rossing N. Intra- and extravascular distribution of albumin and immunoglobulin in man. Lymphology. 1978 Dec;11(4):138–142.
   Google Scholar
• Katz J, Bonorris G, Sellers AL. Extravascular albumin in human tissues. Clin Sci. 1970 Dec;39(6):725–729.
   Google Scholar
• Bert JL, Pearce RH, Mathieson JM. Concentration of plasma albumin in its accessible space in postmortem human dermis. Microvasc Res. 1986 Sep;32(2):211–223.
   Google Scholar
• Wiig H, Gyenge C, Iversen PO, et al. The role of the extracellular matrix in tissue distribution of macromolecules in normal and pathological tissues: potential therapeutic consequences. Microcirculation. 2008 May;15(4):283–296.
   Google Scholar
• Rabilloud T, Asselineau D, Darmon M. Presence of serum albumin in normal human epidermis: possible implications for the nutrition and physiology of stratified epithelia. Presence of albumin in epidermis. Mol Biol Rep. 1988;13(4):213–219.
   Google Scholar
• Larsen MT, Kuhlmann M, Hvam ML, et al. Albumin-based drug delivery: harnessing nature to cure disease. Mol Cell Ther. 2016;4:3.
   Google Scholar
• Sleep D. Albumin and its application in drug delivery. Expert Opin Drug Deliv. 2015 May;12(5):793–812.
   Google Scholar
• Sleep D, Cameron J, Evans LR. Albumin as a versatile platform for drug half-life extension. Biochim Biophys Acta. 2013 Dec;1830(12):5526–5534.
   Google Scholar
• Hermansen K, Fontaine P, Kukolja KK, et al. Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes. Diabetologia. 2004 Apr;47(4):622–629.
   Google Scholar
• Luddeke HJ, Sreenan S, Aczel S, et al. PREDICTIVE- a global, prospective observational study to evaluate insulin detemir treatment in types 1 and 2 diabetes: baseline characteristics and predictors of hypoglycaemia from the European cohort. Diabetes Obes Metab. 2007 May;9(3):428–434.
   Google Scholar
• Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016 Jul 28;375(4):311–322.
   Google Scholar
• Marre M, Shaw J, Brandle M, et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabet Med. 2009 Mar;26(3):268–278.
   Google Scholar
• Elsadek B, Kratz F. Impact of albumin on drug delivery–new applications on the horizon. J Control Release. 2012 Jan 10;157(1):4–28.
   Google Scholar
• Gradishar WJ, Krasnojon D, Cheporov S, et al. Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer. J Clin Oncol. 2009 Aug 1;27(22):3611–3619.
   Google Scholar
• Home PD, Ahren B, Reusch JEB, et al. Three-year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: long-term efficacy with or without rescue therapy. Diabetes Res Clin Pract. 2017 Sep;131:49–60.
   Google Scholar
• GlaxoSmithKline. A study to determine the safety, tolerability, and effects of GSK2374697 in healthy volunteers clinicalTrials.gov. [cited 2020]. Available from: https://clinicaltrials.gov/ct2/show/NCT01545570
   Google Scholar
• Celgene. ABI-008 trial in patients with hormone-refractory prostate cancer clinicalTrials.gov. [cited 2020 Jul 5]. Available from: https://clinicaltrials.gov/ct2/show/NCT00477529
   Google Scholar
• Aadi. A phase 2 study of ABI-009 in patients with advanced malignant PEComa (AMPECT) ClinicalTrials.gov. [cited 2020 Jul 5]. Available from: https://clinicaltrials.gov/ct2/show/NCT02494570
   Google Scholar
• Celgene. A trial of ABI-010 & ABI-007 in patients with advanced non-hematologic malignancies ClinicalTrials.gov. [cited 2020 Jul 5]. Available from: https://clinicaltrials.gov/ct2/show/NCT00820768
   Google Scholar
• Teva Pharmaceutical Industries. Neugranin in breast cancer patients receiving doxorubicin/docetaxel (NEUGR-003) (NEUGR-003) ClinicalTrials.gov. [cited 2020 Jul 5]. Available from: https://clinicaltrials.gov/ct2/show/NCT01126190
   Google Scholar
• Behring CSL. Study of recombinant factor viia fusion protein (rVIIa-FP, CSL689) for on-demand treatment of bleeding episodes in patients with hemophilia A or B with inhibitors ClinicalTrials.gov. [cited 2020 Jul 5]. Available from: https://clinicaltrials.gov/ct2/show/NCT02484638
   Google Scholar
• Beijing Bio-Fortune Ltd. Recombinant human serum albumin/interferon alpha2a fusion protein phase i study in chinese healthy volunteers ClinicalTrials.gov. [cited 2020 Jul 5]. Available from: https://clinicaltrials.gov/ct2/show/NCT01901198
   Google Scholar
• Vasgene Therapeutics I. Recombinant albumin fusion protein sEphB4-HSA in treating patients with metastatic or recurrent solid tumors ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT01642342
   Google Scholar
• Brodersen R, Andersen S, Jacobsen C, et al. Determination of reserve albumin-equivalent for ligand binding, probing two distinct binding functions of the protein. Anal Biochem. 1982 Apr;121(2):395–408.
   Google Scholar
• Ebbesen F, Jacobsen J. Bilirubin-albumin binding affinity and serum albumin concentration during intensive phototherapy (blue double light) in jaundiced newborn infants. Eur J Pediatr. 1980 Sep;134(3):261–263.
   Google Scholar
• Adams PA, Berman MC. Kinetics and mechanism of the interaction between human serum albumin and monomeric haemin. Biochem J. 1980 Oct 1;191(1):95–102.
   Google Scholar
• Zunszain PA, Ghuman J, Komatsu T, et al. Crystal structural analysis of human serum albumin complexed with hemin and fatty acid. BMC Struct Biol. 2003 7; Jul(3): 6.
   Google Scholar
• Richieri GV, Anel A, Kleinfeld AM. Interactions of long-chain fatty acids and albumin: determination of free fatty acid levels using the fluorescent probe ADIFAB. Biochemistry. 1993 Jul 27;32(29):7574–7580.
   Google Scholar
• Bhattacharya AA, Grune T, Curry S. Crystallographic analysis reveals common modes of binding of medium and long-chain fatty acids to human serum albumin. J Mol Biol. 2000 Nov 10;303(5):721–732.
   Google Scholar
• Yates FE, Urquhart J. Control of plasma concentrations of adrenocortical hormones. Physiol Rev. 1962 Jul;42(3):359–433.
   Google Scholar
• Ramsey BL, Westphal U. Steroid-protein interactions. 40. The effect of fatty acids on progesterone binding to human serum albumin. Biochim Biophys Acta. 1978 Apr 28;529(1):115–122.
   Google Scholar
• Pearlman WH, Crepy O. Steroid-protein interaction with particular reference to testosterone binding by human serum. J Biol Chem. 1967 Jan 25;242(2):182–189.
   Google Scholar
• Richardson KS, Nowaczynski W, Genest J. Specific aldosterone-binding proteins in human plasma: partial characterisation. J Steroid Biochem. 1977 Sep;8(9):951–957.
   Google Scholar
• Sugio S, Kashima A, Mochizuki S, et al. Crystal structure of human serum albumin at 2.5 A resolution. Protein Eng. 1999 Jun;12(6):439–446.
   Google Scholar
• Olivieri JR, Craievich AF. The subdomain structure of human serum albumin in solution under different pH conditions studied by small angle X-ray scattering. Eur Biophys J. 1995;24(2):77–84.
   Google Scholar
• Rothschild MA, Oratz M, Schreiber SS. Serum albumin. Hepatology. 1988 Mar-Apr;8(2):385–401.
   Google Scholar
• Carter DC, Ho JX. Structure of serum albumin. Adv Protein Chem. 1994;45:153–203.
   Google Scholar
• Bhattacharya AA, Curry S, Franks NP. Binding of the general anesthetics propofol and halothane to human serum albumin. High resolution crystal structures. Biol Chem. 2000 Dec 8;275(49):38731–38738.
   Google Scholar
• Yang F, Zhang Y, Liang H. Interactive association of drugs binding to human serum albumin. Int J Mol Sci. 2014 Feb 27;15(3):3580–3595.
   Google Scholar
• Simard JR, Zunszain PA, Ha CE, et al. Locating high-affinity fatty acid-binding sites on albumin by x-ray crystallography and NMR spectroscopy. Proc Natl Acad Sci U S A. 2005 Dec 13;102(50):17958–17963.
   Google Scholar
• van der Vusse GJ. Albumin as fatty acid transporter. Drug Metab Pharmacokinet. 2009;24(4):300–307.
   Google Scholar
• Ashbrook JD, Spectro AA, Fletcher JE. Medium chain fatty acid binding to human plasma albumin. J Biol Chem. 1972 Nov 10;247(21):7038–7042.
   Google Scholar
• Ashbrook JD, Spector AA, Santos EC, et al. Long chain fatty acid binding to human plasma albumin. J Biol Chem. 1975 Mar 25;250(6):2333–2338.
   Google Scholar
• Spector AA. Fatty acid binding to plasma albumin. J Lipid Res. 1975 May;16(3):165–179.
   Google Scholar
• Fasano M, Curry S, Terreno E, et al. The extraordinary ligand binding properties of human serum albumin. IUBMB Life. 2005 Dec;57(12):787–796.
   Google Scholar
• Thomas MP, Nelson G, Patonay G, et al. Analysis of drug binding sites on human serum albumin using multidimensional fluorescence measurements. Spectrochim Acta Part B. 1988;43(4–5):651–660.
   Google Scholar
• Henry RA, Wosilait WD. Drug displacement of warfarin from human serum albumin: a fluorometric analysis. Toxicol Appl Pharmacol. 1975 Aug;33(2):267–275.
   Google Scholar
• Torres MJ, Turell L, Botti H, et al. Modulation of the reactivity of the thiol of human serum albumin and its sulfenic derivative by fatty acids. Arch Biochem Biophys. 2012 May;521(1–2):102–110.
   Google Scholar
• Quinlan GJ, Martin GS, Evans TW. Albumin: biochemical properties and therapeutic potential. Hepatology. 2005 Jun;41(6):1211–1219.
   Google Scholar
• Christodoulou J, Sadler PJ, Tucker A. A new structural transition of serum albumin dependent on the state of Cys34. Detection by 1H-NMR spectroscopy. Eur J Biochem. 1994 Oct 1;225(1):363–368.
   Google Scholar
• Schmokel J, Voldum A, Tsakiridou G, et al. Site-selective conjugation of an anticoagulant aptamer to recombinant albumins and maintenance of neonatal Fc receptor binding. Nanotechnology. 2017 May 19;28(20):204004.
   Google Scholar
• Petersen SS, Klaning E, Ebbesen MF, et al. Neonatal Fc receptor binding tolerance toward the covalent conjugation of payloads to cysteine 34 of human albumin variants. Mol Pharm. 2016 Feb 1;13(2):677–682.
   Google Scholar
• Martin WL, West AP Jr., Gan L, et al. Crystal structure at 2.8 A of an FcRn/heterodimeric Fc complex: mechanism of pH-dependent binding. Mol Cell. 2001 Apr;7(4):867–877.
   Google Scholar
• Schmidt MM, Townson SA, Andreucci AJ, et al. Crystal structure of an HSA/FcRn complex reveals recycling by competitive mimicry of HSA ligands at a pH-dependent hydrophobic interface. Structure. 2013 Nov 5;21(11):1966–1978.
   Google Scholar
• Israel EJ, Taylor S, Wu Z, et al. Expression of the neonatal Fc receptor, FcRn, on human intestinal epithelial cells. Immunology. 1997 Sep;92(1):69–74.
   Google Scholar
• Fan YY, Farrokhi V, Caiazzo T, et al. Human FcRn tissue expression profile and half-life in PBMCs. Biomolecules. 2019 Aug 15;9(8). DOI:10.3390/biom9080373.
   Google Scholar
• Latvala S, Jacobsen B, Otteneder MB, et al. Distribution of FcRn across species and tissues. J Histochem Cytochem. 2017 Jun;65(6):321–333.
   Google Scholar
• Li T, Balthasar JP. FcRn expression in wildtype mice, transgenic mice, and in human tissues. Biomolecules. 2018 Oct 15;8(4):115.
   Google Scholar
• Sand KM, Bern M, Nilsen J, et al. Unraveling the interaction between FcRn and albumin: opportunities for design of albumin-based therapeutics. Front Immunol. 2014;5:682.
   Google Scholar
• Chaudhury C, Mehnaz S, Robinson JM, et al. The major histocompatibility complex-related Fc receptor for IgG (FcRn) binds albumin and prolongs its lifespan. J Exp Med. 2003 Feb 3;197(3):315–322.
   Google Scholar
• Schmidt EGW, Hvam ML, Antunes F, et al. Direct demonstration of a neonatal Fc receptor (FcRn)-driven endosomal sorting pathway for cellular recycling of albumin. J Biol Chem. 2017 Aug 11;292(32):13312–13322.
   Google Scholar
• Larsen MT, Rawsthorne H, Schelde KK, et al. Cellular recycling-driven in vivo half-life extension using recombinant albumin fusions tuned for neonatal Fc receptor (FcRn) engagement. J Control Release. 2018 Oct 10;287:132–141.
   Google Scholar
• Andersen JT, Dalhus B, Cameron J, et al. Structure-based mutagenesis reveals the albumin-binding site of the neonatal Fc receptor. Nat Commun. 2012 Jan 3;3:610.
   Google Scholar
• Sand KM, Dalhus B, Christianson GJ, et al. Dissection of the neonatal Fc receptor (FcRn)-albumin interface using mutagenesis and anti-FcRn albumin-blocking antibodies. J Biol Chem. 2014 Jun 13;289(24):17228–17239.
   Google Scholar
• Nilsen J, Bern M, Sand KMK, et al. Human and mouse albumin bind their respective neonatal Fc receptors differently. Sci Rep. 2018 Oct 2;8(1):14648.
   Google Scholar
• Andersen JT, Dee Qian J, Sandlie I. The conserved histidine 166 residue of the human neonatal Fc receptor heavy chain is critical for the pH-dependent binding to albumin. Eur J Immunol. 2006 Nov;36(11):3044–3051.
   Google Scholar
• Chaudhury C, Brooks CL, Carter DC, et al. Albumin binding to FcRn: distinct from the FcRn-IgG interaction. Biochemistry. 2006 Apr 18;45(15):4983–4990.
   Google Scholar
• Oganesyan V, Damschroder MM, Cook KE, et al. Structural insights into neonatal Fc receptor-based recycling mechanisms. J Biol Chem. 2014 Mar 14;289(11):7812–7824.
   Google Scholar
• Sand KM, Bern M, Nilsen J, et al. Interaction with both domain I and III of albumin is required for optimal pH-dependent binding to the neonatal Fc receptor (FcRn). J Biol Chem. 2014 Dec 12;289(50):34583–34594.
   Google Scholar
• Schnitzer JE, Carley WW, Palade GE. Albumin interacts specifically with a 60-kDa microvascular endothelial glycoprotein. Proc Natl Acad Sci U S A. 1988 Sep;85(18):6773–6777.
   Google Scholar
• Tiruppathi C, Song W, Bergenfeldt M, et al. Gp60 activation mediates albumin transcytosis in endothelial cells by tyrosine kinase-dependent pathway. J Biol Chem. 1997 Oct 10;272(41):25968–25975.
   Google Scholar
• Schnitzer JE. gp60 is an albumin-binding glycoprotein expressed by continuous endothelium involved in albumin transcytosis. Am J Physiol. 1992 Jan;262(1 Pt 2):H246–54.
   Google Scholar
• Vogel SM, Minshall RD, Pilipovic M, et al. Albumin uptake and transcytosis in endothelial cells in vivo induced by albumin-binding protein. Am J Physiol Lung Cell Mol Physiol. 2001 Dec;281(6):L1512–22.
   Google Scholar
• John TA, Vogel SM, Tiruppathi C, et al. Quantitative analysis of albumin uptake and transport in the rat microvessel endothelial monolayer. Am J Physiol Lung Cell Mol Physiol. 2003 Jan;284(1):L187–96.
   Google Scholar
• Pardridge WM, Eisenberg J, Cefalu WT. Absence of albumin receptor on brain capillaries in vivo or in vitro. Am J Physiol. 1985 Sep;249(3 Pt 1):E264–7.
   Google Scholar
• Tiruppathi C, Finnegan A, Malik AB. Isolation and characterization of a cell surface albumin-binding protein from vascular endothelial cells. Proc Natl Acad Sci U S A. 1996 Jan 9;93(1):250–254.
   Google Scholar
• Schnitzer JE, Oh P. Albondin-mediated capillary permeability to albumin. Differential role of receptors in endothelial transcytosis and endocytosis of native and modified albumins. J Biol Chem. 1994 Feb 25;269(8):6072–6082.
   Google Scholar
• Miyawaki-Shimizu K, Predescu D, Shimizu J, et al. siRNA-induced caveolin-1 knockdown in mice increases lung vascular permeability via the junctional pathway. Am J Physiol Lung Cell Mol Physiol. 2006 Feb;290(2):L405–13.
   Google Scholar
• Minshall RD, Tiruppathi C, Vogel SM, et al. Endothelial cell-surface gp60 activates vesicle formation and trafficking via G(i)-coupled Src kinase signaling pathway. J Cell Biol. 2000 Sep 4;150(5):1057–1070.
   Google Scholar
• Chatterjee M, Ben-Josef E, Robb R, et al. Caveolae-mediated endocytosis is critical for albumin cellular uptake and response to albumin-bound chemotherapy. Cancer Res. 2017 Nov 1;77(21):5925–5937.
   Google Scholar
• John TA, Vogel SM, Minshall RD, et al. Evidence for the role of alveolar epithelial gp60 in active transalveolar albumin transport in the rat lung. J Physiol. 2001 Jun 1;533(Pt 2):547–559.
   Google Scholar
• Raheel H, Ghaffari S, Khosraviani N, et al. CD36 mediates albumin transcytosis by dermal but not lung microvascular endothelial cells: role in fatty acid delivery. Am J Physiol Lung Cell Mol Physiol. 2019 May 1;316(5):L740–L750.
   Google Scholar
• Febbraio M, Hajjar DP, Silverstein RL. CD36: a class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism. J Clin Invest. 2001 Sep;108(6):785–791.
   Google Scholar
• Schnitzer JE, Sung A, Horvat R, et al. Preferential interaction of albumin-binding proteins, gp30 and gp18, with conformationally modified albumins. Presence in many cells and tissues with a possible role in catabolism. J Biol Chem. 1992 Dec 5;267(34):24544–24553.
   Google Scholar
• Schnitzer JE, Bravo J. High affinity binding, endocytosis, and degradation of conformationally modified albumins. Potential role of gp30 and gp18 as novel scavenger receptors. J Biol Chem. 1993 Apr 5;268(10):7562–7570.
   Google Scholar
• Home P, Kurtzhals P. Insulin detemir: from concept to clinical experience. Expert Opin Pharmacother. 2006 Feb;7(3):325–343.
   Google Scholar
• Affairs DoV. Department of defense. VA/DoD clinical practice guideline for the management of type 2 diabetes mellitus in primary care. 2017.
   Google Scholar
• FDA. NovoLog® insulin aspart (rDNA origin) injection. [cited 2020 Jul 5]. Available from: https://www.accessdata.fda.gov/: FDA. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/020986s033lbl.pdf
   Google Scholar
• FDA. Prescribing informations of HUMULIN R: FDA. [cited 2020 Jul 5]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/018780s126s134lbl.pdf
   Google Scholar
• Novo Nordisk Inc. Levemir® (insulin detemir injection): prescribing information. [cited 2020 Jul 5]. Available from: https://www.novo-pi.com/levemir.pdf
   Google Scholar
• Morales J. Defining the role of insulin detemir in Basal insulin therapy. Drugs. 2007;67(17):2557–2584.
   Google Scholar
• Jacobsen LV, Flint A, Olsen AK, et al. Liraglutide in type 2 diabetes mellitus: clinical pharmacokinetics and pharmacodynamics. Clin Pharmacokinet. 2016 Jun;55(6):657–672.
   Google Scholar
• Novo Nordisk Inc. Victoza® (Liraglutide injection): prescribing information. [cited 2020]. Available from: https://www.novo-pi.com/victoza.pdf
   Google Scholar
• Gradel AKJ, Porsgaard T, Lykkesfeldt J, et al. Factors affecting the absorption of subcutaneously administered insulin: effect on variability. J Diabetes Res. 2018;2018:1205121.
   Google Scholar
• Hvam ML, Cai Y, Dagnaes-Hansen F, et al. Fatty acid-modified gapmer antisense oligonucleotide and serum albumin constructs for pharmacokinetic modulation. Mol Ther. 2017 Jul 5;25(7):1710–1717.
   Google Scholar
• Bienk K, Hvam ML, Pakula MM, et al. An albumin-mediated cholesterol design-based strategy for tuning siRNA pharmacokinetics and gene silencing. J Control Release. 2016 Jun 28;232:143–151.
   Google Scholar
• Soutschek J, Akinc A, Bramlage B, et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature. 2004 Nov 11;432(7014):173–178.
   Google Scholar
• Sarett SM, Werfel TA, Lee L, et al. Lipophilic siRNA targets albumin in situ and promotes bioavailability, tumor penetration, and carrier-free gene silencing. Proc Natl Acad Sci U S A. 2017 Aug 8;114(32):E6490–E6497.
   Google Scholar
• Walker A, Dunlevy G, Rycroft D, et al. Anti-serum albumin domain antibodies in the development of highly potent, efficacious and long-acting interferon. Protein Eng Des Sel. 2010 Apr;23(4):271–278.
   Google Scholar
• Holt LJ, Basran A, Jones K, et al. Anti-serum albumin domain antibodies for extending the half-lives of short lived drugs. Protein Eng Des Sel. 2008 May;21(5):283–288.
   Google Scholar
• O’Connor-Semmes RL, Lin J, Hodge RJ, et al. GSK2374697, a novel albumin-binding domain antibody (AlbudAb), extends systemic exposure of exendin-4: first study in humans–PK/PD and safety. Clin Pharmacol Ther. 2014 Dec;96(6):704–712.
   Google Scholar
• Thorneloe KS, Sepp A, Zhang S, et al. The biodistribution and clearance of AlbudAb, a novel biopharmaceutical medicine platform, assessed via PET imaging in humans. EJNMMI Res. 2019 May 21;9(1):45.
   Google Scholar
• GlaxoSmithKline. A positron emission tomography (PET) imaging study to investigate the biodistribution and clearance of an albumin binding domain antibody (AlbudAb) GSK3128349 in healthy male subjects ClinicalTrials.gov [cited 2020]. Available from: https://clinicaltrials.gov/ct2/show/NCT02829307
   Google Scholar
• Revets H, De Baetselier P, Muyldermans S. Nanobodies as novel agents for cancer therapy. Expert Opin Biol Ther. 2005 Jan;5(1):111–124.
   Google Scholar
• Muyldermans S. Nanobodies: natural single-domain antibodies. Annu Rev Biochem. 2013;82:775–797.
   Google Scholar
• Van Roy M, Ververken C, Beirnaert E, et al. The preclinical pharmacology of the high affinity anti-IL-6R Nanobody(R) ALX-0061 supports its clinical development in rheumatoid arthritis. Arthritis Res Ther. 2015 May 20;17:135.
   Google Scholar
• Jovcevska I, Muyldermans S. The therapeutic potential of nanobodies. BioDrugs. 2020 Feb;34(1):11–26.
   Google Scholar
• Ablynx. A phase IIb study for ALX-0061 monotherapy in subjects with rheumatoid arthritis ClinicalTrials.gov. [cited 2020 Jul 5]. Available from: https://clinicaltrials.gov/ct2/show/results/NCT02287922
   Google Scholar
• Ablynx. A dose-range finding study for ALX-0061 combination therapy in subjects with rheumatoid arthritis ClinicalTrials.gov. [cited 2020 Jul 5]. Available from: https://clinicaltrials.gov/ct2/show/results/NCT02309359
   Google Scholar
• Taisho Pharmaceutical Co. An extension study of TS-152 in subjects with rheumatoid arthritis ClinicalTrials.gov [cited 2020]. Available from: https://clinicaltrials.gov/ct2/show/NCT04077567
   Google Scholar
• Kratz F, Elsadek B. Clinical impact of serum proteins on drug delivery. J Control Release. 2012 Jul 20;161(2):429–445.
   Google Scholar
• Nilvebrant J, Hober S. The albumin-binding domain as a scaffold for protein engineering. Comput Struct Biotechnol J. 2013;6:e201303009.
   Google Scholar
• Zorzi A, Linciano S, Angelini A. Non-covalent albumin-binding ligands for extending the circulating half-life of small biotherapeutics. Medchemcomm. 2019 Jul 1;10(7):1068–1081.
   Google Scholar
• Jonsson A, Dogan J, Herne N, et al. Engineering of a femtomolar affinity binding protein to human serum albumin. Protein Eng Des Sel. 2008 Aug;21(8):515–527.
   Google Scholar
• Tolmachev V, Orlova A, Pehrson R, et al. Radionuclide therapy of HER2-positive microxenografts using a 177Lu-labeled HER2-specific Affibody molecule. Cancer Res. 2007 Mar 15;67(6):2773–2782.
   Google Scholar
• Guo R, Guo W, Cao L, et al. Fusion of an albumin-binding domain extends the half-life of immunotoxins. Int J Pharm. 2016 Sep 10;511(1):538–549.
   Google Scholar
• Li R, Yang H, Jia D, et al. Fusion to an albumin-binding domain with a high affinity for albumin extends the circulatory half-life and enhances the in vivo antitumor effects of human TRAIL. J Control Release. 2016 Apr 28;228:96–106.
   Google Scholar
• Celgene Corporation. ABRAXANE® for injectable suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound). [cited 2020 Jul 5]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021660s037lbl.pdf
   Google Scholar
• Desai N, Trieu V, Yao Z, et al. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res. 2006 Feb 15;12(4):1317–1324.
   Google Scholar
• Gradishar WJ, Tjulandin S, Davidson N, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol. 2005 Nov 1;23(31):7794–7803.
   Google Scholar
• FDA. Prescribing informations of TANZEUM: FDA. [cited 2020 Jul 5]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125431s019lbl.pdf
   Google Scholar
• Matthews JE, Stewart MW, De Boever EH, et al. Pharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in patients with type 2 diabetes. J Clin Endocrinol Metab. 2008 Dec;93(12):4810–4817.
   Google Scholar
• Woodward HN, Anderson SL. Once-weekly albiglutide in the management of type 2 diabetes: patient considerations. Patient Prefer Adherence. 2014;8:789–803.
   Google Scholar
• Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al. Guidelines for the management of hemophilia. Haemophilia. 2013 Jan;19(1):e1–47.
   Google Scholar
• White GC 2nd, Beebe A, Nielsen B. Recombinant factor IX. Thromb Haemost. 1997 Jul;78(1):261–265.
   Google Scholar
• Bjorkman S, Shapiro AD, Berntorp E. Pharmacokinetics of recombinant factor IX in relation to age of the patient: implications for dosing in prophylaxis. Haemophilia. 2001 Mar;7(2):133–139.
   Google Scholar
• Chia J, Louber J, Glauser I, et al. Half-life-extended recombinant coagulation factor IX-albumin fusion protein is recycled via the FcRn-mediated pathway. J Biol Chem. 2018 Apr 27;293(17):6363–6373.
   Google Scholar
• Metzner HJ, Weimer T, Kronthaler U, et al. Genetic fusion to albumin improves the pharmacokinetic properties of factor IX. Thromb Haemost. 2009 Oct;102(4):634–644.
   Google Scholar
• Santagostino E, Martinowitz U, Lissitchkov T, et al. Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial. Blood. 2016 Apr 7;127(14):1761–1769.
   Google Scholar
• Zeuzem S, Yoshida EM, Benhamou Y, et al. Albinterferon alfa-2b dosed every two or four weeks in interferon-naive patients with genotype 1 chronic hepatitis C. Hepatology. 2008 Aug;48(2):407–417.
   Google Scholar
• Bain VG, Kaita KD, Yoshida EM, et al. A phase 2 study to evaluate the antiviral activity, safety, and pharmacokinetics of recombinant human albumin-interferon alfa fusion protein in genotype 1 chronic hepatitis C patients. J Hepatol. 2006 Apr;44(4):671–678.
   Google Scholar
• Colvin RA, Tanwandee T, Piratvisuth T, et al. Randomized, controlled pharmacokinetic and pharmacodynamic evaluation of albinterferon in patients with chronic hepatitis B infection. J Gastroenterol Hepatol. 2015 Jan;30(1):184–191.
   Google Scholar
• Zeuzem S, Sulkowski MS, Lawitz EJ, et al. Albinterferon Alfa-2b was not inferior to pegylated interferon-alpha in a randomized trial of patients with chronic hepatitis C virus genotype 1. Gastroenterology. 2010 Oct;139(4):1257–1266.
   Google Scholar
• Prescription Drug Information ISe. Zalbin approval status [cited 2020]. Available from: http://www.drugs.com/history/zalbin.html
   Google Scholar
• Wong SS. Chemistry of protein conjugation and cross-linking. Boca Raton (FL): CRC press; 1991.
   Google Scholar
• CytRx. Phase 3 study to treat patients with soft tissue sarcomas ClinicalTrials.gov. [cited 2020 Jul 5]. Available from: https://clinicaltrials.gov/ct2/show/NCT02049905
   Google Scholar
• Gong J, Yan J, Forscher C, et al. Aldoxorubicin: a tumor-targeted doxorubicin conjugate for relapsed or refractory soft tissue sarcomas. Drug Des Devel Ther. 2018;12:777–786.
   Google Scholar
• Cranmer LD. Spotlight on aldoxorubicin (INNO-206) and its potential in the treatment of soft tissue sarcomas: evidence to date. Onco Targets Ther. 2019;12:2047–2062.
   Google Scholar
• Mita MM, Natale RB, Wolin EM, et al. Pharmacokinetic study of aldoxorubicin in patients with solid tumors. Invest New Drugs. 2015 Apr;33(2):341–348.
   Google Scholar
• Chawla SP, Ganjoo KN, Schuetze S, et al. Phase III study of aldoxorubicin vs investigators’ choice as treatment for relapsed/refractory soft tissue sarcomas. Am Soc Clin Oncol. 2017;35. DOI:10.1200/JCO.2017.35.15_suppl.11000.
   Google Scholar
• Prescription Drug Information ISe. Doxorubicin. [cited 2020]. Available from: https://www.drugs.com/pro/doxorubicin.html
   Google Scholar
• Lau S, Graham B, Cao N, et al. Enhanced extravasation, stability and in vivo cardiac gene silencing via in situ siRNA-albumin conjugation. Mol Pharm. 2012 Jan 1;9(1):71–80.
   Google Scholar
• Stehle G, Sinn H, Wunder A, et al. The loading rate determines tumor targeting properties of methotrexate-albumin conjugates in rats. Anticancer Drugs. 1997 Aug;8(7):677–685.
   Google Scholar
• Fiehn C, Muller-Ladner U, Gay S, et al. Albumin-coupled methotrexate (MTX-HSA) is a new anti-arthritic drug which acts synergistically to MTX. Rheumatology (Oxford). 2004 Sep;43(9):1097–1105.
   Google Scholar
• Vis AN, van der Gaast A, van Rhijn BW, et al. A phase II trial of methotrexate-human serum albumin (MTX-HSA) in patients with metastatic renal cell carcinoma who progressed under immunotherapy. Cancer Chemother Pharmacol. 2002 Apr;49(4):342–345.
   Google Scholar
• Hartung G, Stehle G, Sinn H, et al. Phase I trial of methotrexate-albumin in a weekly intravenous bolus regimen in cancer patients. Phase i study group of the association for medical oncology of the German cancer society. Clin Cancer Res. 1999 Apr;5(4):753–759.
   Google Scholar
• Bolling C, Graefe T, Lubbing C, et al. Phase II study of MTX-HSA in combination with cisplatin as first line treatment in patients with advanced or metastatic transitional cell carcinoma. Invest New Drugs. 2006 Nov;24(6):521–527.
   Google Scholar
• ConjuChem LCC. About DAC™ http://www.conjuchem.com/: conjuChem LCC. [cited 2020 Jul 5]. Available from: http://www.conjuchem.com/technology/dac
   Google Scholar
• ConjuChem LCC. About PC-DAC™ http://www.conjuchem.com/: conjuChem LCC. [cited 2020 Jul 5]. Available from: http://www.conjuchem.com/technology/pc-dac
   Google Scholar
• LCC C. A study to evaluate the efficacy and safety of CJC-1134-PC in patients with type 2 diabetes who are currently on metformin monotherapy ClinicalTrials.gov. [cited 2020 Jul 5]. Available from: https://clinicaltrials.gov/ct2/show/results/NCT00674466
   Google Scholar
• LCC C. A study to evaluate the efficacy and safety of CJC-1134-PC in patients with type 2 diabetes mellitus who are currently on metformin monotherapy (DM200-101) ClinicalTrials.gov. [cited 2020 Jul 5]. Available from: https://clinicaltrials.gov/ct2/show/results/NCT00638716
   Google Scholar
• Shen BQ, Xu K, Liu L, et al. Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates. Nat Biotechnol. 2012 Jan 22;30(2):184–189.
   Google Scholar
• Smith ME, Caspersen MB, Robinson E, et al. A platform for efficient, thiol-stable conjugation to albumin’s native single accessible cysteine. Org Biomol Chem. 2015 Aug 7;13(29):7946–7949.
   Google Scholar
• Wall A, Nicholls K, Caspersen MB, et al. Optimised approach to albumin-drug conjugates using monobromomaleimide-C-2 linkers. Org Biomol Chem. 2019 Aug 28;17(34):7870–7873.
   Google Scholar
• Rahbek UL, Howard KA, Oupicky D, et al. Intracellular siRNA and precursor miRNA trafficking using bioresponsive copolypeptides. J Gene Med. 2008 Jan;10(1):81–93.
   Google Scholar
• Iwao Y, Hiraike M, Kragh-Hansen U, et al. Changes of net charge and alpha-helical content affect the pharmacokinetic properties of human serum albumin. Biochim Biophys Acta. 2007 Dec;1774(12):1582–1590.
   Google Scholar
• Iwao Y, Hiraike M, Kragh-Hansen U, et al. Altered chain-length and glycosylation modify the pharmacokinetics of human serum albumin. Biochim Biophys Acta. 2009 Apr;1794(4):634–641.
   Google Scholar
• Andersen JT, Dalhus B, Viuff D, et al. Extending serum half-life of albumin by engineering neonatal Fc receptor (FcRn) binding. J Biol Chem. 2014 May 9;289(19):13492–13502.
   Google Scholar
• Larsen MT, Mandrup OA, Schelde KK, et al. FcRn overexpression in human cancer drives albumin recycling and cell growth; a mechanistic basis for exploitation in targeted albumin-drug designs. J Control Release. 2020 Mar 4;322:53–63.
   Google Scholar
• Schelde KK, Nicholls K, Dagnaes-Hansen F, et al. A new class of recombinant human albumin with multiple surface thiols exhibits stable conjugation and enhanced FcRn binding and blood circulation. J Biol Chem. 2019 Mar 8;294(10):3735–3743.
   Google Scholar
• Pyzik M, Sand KMK, Hubbard JJ, et al. The Neonatal Fc Receptor (FcRn): a misnomer? Front Immunol. 2019;10:1540.
   Google Scholar
• Andersen JT, Daba MB, Berntzen G, et al. Cross-species binding analyses of mouse and human neonatal Fc receptor show dramatic differences in immunoglobulin G and albumin binding. J Biol Chem. 2010 Feb 12;285(7):4826–4836.
   Google Scholar
• Viuff D, Antunes F, Evans L, et al. Generation of a double transgenic humanized neonatal Fc receptor (FcRn)/albumin mouse to study the pharmacokinetics of albumin-linked drugs. J Control Release. 2016 Feb 10;223:22–30.
   Google Scholar
• Kuhlmann M, Hamming JBR, Voldum A, et al. An albumin-oligonucleotide assembly for potential combinatorial drug delivery and half-life extension applications. Mol Ther Nucleic Acids. 2017 Dec 15;9:284–293.
   Google Scholar